Updates in Pathogenesis and Treatment of Severe Atopic Dermatitis

Research has revealed that immune system is skewed towards type 2 immunity in the skin, which can be effectively suppressed with targeted therapeutics directed against this shift, particularly inhibitors of the IL-4/IL-13 pathway and downstream JAK-STATs. This presentation will highlight new and emerging agents for pediatric AD, linking their action to the mechanism of disease. Particularly for children, the safety of targeted biologics has been welcome, but the pain associated with injections is a challenge for many families. The approach to the family with a child suffering from severe atopic dermatitis will be shared, highlighting tips and tricks.